Transcode Therapeutics Inc
Change company Symbol lookup
Select an option...
RNAZ Transcode Therapeutics Inc
NVAX Novavax Inc
EBIX Ebix Inc
FCRD First Eagle Alternative Capital BDC Inc
RWAY Runway Growth Finance Corp
LITB LightInTheBox Holding Co Ltd
UEC Uranium Energy Corp
NEE Nextera Energy Inc
MANT ManTech International Corp
AMPE Ampio Pharmaceuticals Inc
Go

Health Care : Biotechnology |
Company profile

TransCode Therapeutics, Inc. is a ribonucleic acid (RNA) oncology company. The Company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer. TTX-MC138 comprises proprietary iron-oxide nanoparticles and oligonucleotides that specifically target microRNA-10b. The nanoparticles serve as the vehicle to deliver oligonucleotides to metastatic cancer cells. The magnetic properties of these nanoparticles allow for monitoring of their delivery using non-invasive imaging. Its pipeline products also include TTX-siPDL1, TTX-siLIN28b and TTX-RIGA. TTX-siPDL1 is a checkpoint inhibitor targeting programmed cell death protein ligand 1 (PD-L1). TTX-RIGA utilizes its delivery system and is intended to activate the RIG-I signaling pathway to elicit an immune response to eliminate and/or reduce the risk of developing disorders associated with abnormal apoptotic or differentiative processes, by triggering an immune response that targets developing cancer cells.

Closing Price
$2.51
Day's Change
0.10 (4.15%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.53
Day's Low
2.37
Volume
(Light)
Volume:
44,761

10-day average volume:
76,235
44,761

Display:

Providers:

UpdateCancel
6 providers
January 06, 2022
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based scientific...(Globe Newswire)

December 06, 2021
TransCode Therapeutics To Participate at MedInvest Oncology Investor Conference

TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the MedInvest Oncology Investor Conference. TransCode's Chief Executive Officer, Michael Dudley, will describe the Company's RNA-based...(Globe Newswire)

November 15, 2021
TransCode Therapeutics Reports Business Progress and Third Quarter 2021 Financial Results

TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today reported recent business progress and third...(BusinessWire)

November 09, 2021
TransCode Therapeutics Announces Participation in the Q4 Virtual Investor Summit

Boston, Massachusetts--(Newsfile Corp. - November 9, 2021) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ) today announced that it will be attending and presenting at the Q4 Virtual Investor Summit. TransCode's Chief Executive Officer, Michael Dudley...(Newsfile)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.